Financial Data and Key Metrics Changes - In Q4 2024, ChromaDex reported record revenues of $29.1 million, a 37% increase year-over-year, and net income of $7.2 million [9] - For the full year 2024, net revenues reached $99.6 million, reflecting a 19% growth year-over-year, with net income of $8.6 million, a significant turnaround from a net loss of $4.9 million in 2023 [9][23] - The company generated $12.1 million in positive cash flow from operations in 2024, ending the year with $44.7 million in cash and no debt [10][29] Business Line Data and Key Metrics Changes - E-commerce channel net sales were $17.3 million, a 30% increase year-over-year, while food-grade and pharmaceutical-grade Niagen ingredient sales reached $5.3 million, a 96% increase year-over-year [10][24] - Tru Niagen-related sales increased by 29%, driven by a 30% growth in e-commerce and a 26% increase in combined Watsons and other B2B sales [24] Market Data and Key Metrics Changes - The company noted a strong demand for NAD-boosting products, with a proliferation of companies entering the market, some of which engage in misleading practices [11][12] - The company is seeing increased awareness of NAD and Niagen, particularly following the launch of the Niagen IV product line [10][46] Company Strategy and Development Direction - ChromaDex plans to use its leadership position to drive consumer safety and product excellence, addressing misleading practices in the market [12][13] - The company is pursuing an investigational new drug application for the use of NR in treating ataxia telangiectasia and is working with the FDA on the NO-PARK study for Parkinson's disease [16][111] - A name change is anticipated to better align with the company's mission and strategic direction [17][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, expecting approximately 18% growth in net sales for 2025, driven by e-commerce expansion and established partnerships [31] - The management highlighted the importance of addressing fraudulent practices in the NAD market and emphasized the need for regulatory action [12][106] Other Important Information - Gross margins improved to 61.8% for the full year, reflecting operational efficiency and a favorable product mix [23][25] - General and administrative expenses are expected to increase by approximately $5 million to $6 million in 2025, primarily due to investments in business growth [33][124] Q&A Session Summary Question: Can you discuss the stick packs and their performance? - The stick packs contain 300 milligrams and have seen increased sales, with plans for a marketing campaign in 2025 [36][37] Question: What is the expectation for the second payment from Elysium? - The second payment of $1.3 million from Elysium is expected by the end of March [40][41] Question: When can we expect results from the NO PARK study? - Results are anticipated around the end of Q3 or early Q4, but the company cannot guarantee public disclosure at that time [42][44] Question: How is the food-grade Niagen segment expected to perform in 2025? - The food-grade ingredient business is expected to continue growing, with new partnerships being added [46] Question: What drove the strong e-commerce performance in Q4? - Improvements in Shopify performance, increased awareness of NAD, and publicity contributed to the strong e-commerce results [54][55] Question: What are the supply chain risks associated with Niagen IV? - While there are always risks, the company believes it has resolved previous supply chain issues and is prepared for future demand [60][65] Question: How does the company view the potential market for NR adoption? - The company sees significant potential if the ongoing Parkinson's study yields positive results, with a large addressable market [111][116] Question: Will there be a spinout for pharmaceutical initiatives? - A spinout is a possibility if capital is insufficient for drug approval, but the company does not expect this to be necessary [119][121]

Financial Data and Key Metrics Changes - In Q4 2024, the company reported record revenues of $29.1 million, a 37% increase year-over-year, and net income of $7.2 million [8][23] - For the full year 2024, net revenues reached $99.6 million, reflecting a 19% growth year-over-year, with net income of $8.6 million, a significant turnaround from a net loss of $4.9 million in 2023 [8][22] - The company generated $12.1 million in positive cash flow from operations in 2024, ending the year with $44.7 million in cash and no debt [9][28] Business Line Data and Key Metrics Changes - E-commerce channel net sales were $17.3 million, a 30% increase year-over-year, while food-grade and pharmaceutical-grade Niagen ingredient sales reached $5.3 million, a 96% increase year-over-year [9][24] - Tru Niagen-related sales increased by 29%, driven by a 30% growth in e-commerce and a 26% increase in combined Watsons and other B2B sales [23][24] Market Data and Key Metrics Changes - The company noted a growing demand for NAD-boosting products, with an increase in companies entering the market, some of which engage in misleading practices [10][11] - The company is actively working to address fraudulent activities in the market and is advocating for more regulatory oversight [11][105] Company Strategy and Development Direction - The company plans to leverage its position as an industry leader to promote consumer safety and product excellence [12] - A name change is anticipated to better align with the company's evolving mission and strategic direction [16][33] - The company is focused on expanding its pharmaceutical-grade ingredient business and enhancing its e-commerce presence [30][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the company's strong financial discipline and operational efficiency [22][32] - The company expects approximately 18% growth in net sales for 2025, driven by e-commerce expansion and established partnerships [30][32] - Management acknowledged potential risks related to supply chain issues but indicated confidence in resolving these challenges [62] Other Important Information - The company has initiated communication with the FDA regarding an investigational new drug application for NR in treating ataxia telangiectasia and is awaiting results from the NO-PARK study for Parkinson's disease [15][16] - The company plans to introduce new formulations and enhance existing products, including a subcutaneous injection version of Niagen [84] Q&A Session Summary Question: Can you discuss the stick packs and their performance? - The stick packs contain 300 milligrams and have seen increased sales, with plans for a marketing campaign in 2025 [36] Question: What is the status of the Elysium settlement? - The second payment of $1.3 million from the Elysium settlement is expected by the end of March [40] Question: When can we expect results from the NO-PARK study? - The study will be completed by June, but results may not be available until later [42] Question: How is the food-grade Niagen segment performing? - The food-grade ingredient business is expected to continue growing, with increased awareness and new partnerships [45] Question: What are the drivers behind strong e-commerce performance? - Improvements in Shopify performance and increased awareness of NAD contributed to e-commerce growth [54] Question: What is the company's strategy regarding supply chain risks? - The company has resolved previous supply chain issues and expects to maintain a steady supply moving forward [62] Question: What are the potential market opportunities for the Parkinson's study? - A positive outcome could significantly increase demand, with a large addressable market for those diagnosed with Parkinson's disease [112] Question: Will there be a spin-off for pharmaceutical initiatives? - A spin-off is a possibility if capital is insufficient for drug approval, but it is not currently expected [118]

分组1 - ChromaDex reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to break-even earnings per share a year ago, representing an earnings surprise of 50% [1] - The company achieved revenues of $29.13 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 7.47%, and showing an increase from year-ago revenues of $21.2 million [2] - ChromaDex has outperformed the S&P 500, with shares adding about 3.7% since the beginning of the year, while the S&P 500 declined by 0.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.04 on revenues of $28.55 million, and for the current fiscal year, it is $0.12 on revenues of $120.8 million [7] - The Medical - Biomedical and Genetics industry, to which ChromaDex belongs, is currently in the top 29% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Financial Performance - Full year net sales reached $99.6 million, a 19% increase from the prior year, with a gross margin of 61.8% and net income of $8.6 million[1][5][11] - Fourth quarter net sales were $29.1 million, up 37% year-over-year, with a gross margin of 62.5% and net income of $7.2 million, a significant improvement from $0.1 million in the prior year quarter[1][5][9] - Tru Niagen® sales contributed $22.7 million to fourth quarter net sales, reflecting a 29% increase from the prior year quarter[6][7] - Adjusted EBITDA for the full year was $8.5 million, a $6.6 million improvement from the previous year, while fourth quarter adjusted EBITDA was $3.4 million, up $2.1 million year-over-year[1][10][13] - Net sales for Q4 2024 reached $29,125,000, a 37.5% increase from $21,196,000 in Q4 2023[27] - Gross profit for Q4 2024 was $18,197,000, up 40.5% from $12,937,000 in Q4 2023[27] - Operating income for Q4 2024 was $7,111,000, compared to a loss of $168,000 in Q4 2023[27] - Net income for Q4 2024 was $7,179,000, a significant increase from $114,000 in Q4 2023[27] - Adjusted EBITDA for the full year 2024 was $8,504,000, compared to $1,900,000 in 2023, reflecting a substantial improvement[33] - The company reported a basic net income per share of $0.09 for Q4 2024, compared to a loss of $0.07 per share in Q4 2023[27] Cash and Assets - The company ended the year with $44.7 million in cash and no debt, with operating cash flows of $12.1 million, compared to $7.1 million in the prior year[1][14] - Cash and cash equivalents at the end of 2024 were $44,660,000, up from $27,325,000 in 2023, marking a 63.8% increase[31] - Total current assets increased to $64,102,000 in 2024 from $49,534,000 in 2023, representing a 29.3% growth[29] - Total liabilities decreased to $17,948,000 in 2024 from $20,622,000 in 2023, a reduction of 12.9%[29] Expenses and Projections - General and administrative expenses decreased by $6.6 million year-over-year, primarily due to lower royalty expenses and credit loss recoveries[1][16] - Selling and marketing expenses are expected to increase in absolute dollars but remain stable as a percentage of net sales, reflecting strategic investments in brand awareness[1][17] - Research and development expenses for the full year 2024 were $6,016,000, an increase from $4,958,000 in 2023[27] - For 2025, the company projects approximately 18% year-over-year revenue growth, with slight improvements in gross margin and increased general and administrative expenses of $5.0 to $6.0 million[1][17] Product Development and Regulatory - In 2024, ChromaDex launched Niagen Plus, a new product line featuring pharmaceutical-grade Niagen®, now available at over 475 wellness clinics in the U.S.[1][6] - The company received Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for NR, and is advancing its Investigational New Drug application for Ataxia Telangiectasia[1][6]

Financial Performance - The company recorded a net income of approximately $8.6 million for the year ended December 31, 2024, compared to a net loss of $4.9 million for 2023, with an accumulated deficit of approximately $181.9 million as of December 31, 2024[85]. - Total assets increased to $68,278 million in 2024 from $54,964 million in 2023, representing a growth of 24.1%[266]. - Net sales for 2024 reached $99,597 million, up 19.2% from $83,570 million in 2023[268]. - Gross profit improved to $61,586 million in 2024, a 21.4% increase compared to $50,780 million in 2023[268]. - Operating income turned positive at $7,726 million in 2024, compared to an operating loss of $5,599 million in 2023[268]. - Cash and cash equivalents increased to $44,660 million at the end of 2024, up from $27,325 million at the end of 2023, marking a 63.7% increase[273]. - Total stockholders' equity rose to $46,094 million in 2024 from $28,456 million in 2023, reflecting a growth of 62.0%[266]. - The company anticipates that its current cash and cash equivalents, along with cash generated from net sales, will be sufficient to meet financial obligations for at least the next twelve months[314]. Competition and Market Risks - The company faces significant competition from larger companies with greater financial resources, which may impact its market position and ability to launch new products[94]. - The company faces intense competition in its markets, with competitors potentially developing superior technologies that could harm its business[98]. - Economic conditions, including inflation and geopolitical issues, may negatively impact the company's business, financial condition, and share price, leading to decreased demand for its products[88]. - The success of the company's consumer product business is linked to the growth rate of the wellness industry market, particularly the dietary supplement market[91]. Operational Challenges - The company relies on a single supplier for key raw materials, which poses risks to its production capabilities and overall business operations[84]. - The company relies on contract manufacturers for pharmaceutical-grade Niagen®, and any failure by these facilities could significantly impact the ability to meet consumer demand[124]. - The company may struggle to monetize its products for pharmaceutical applications due to challenges in securing partnerships and regulatory approvals[114]. - The company may need to restructure its operations in response to changing market conditions, which could increase costs and impact profitability[97]. - The company relies on key personnel for its operations, and the loss of any critical team members could adversely affect its business[113]. Regulatory and Compliance Risks - Regulatory approvals for the company's products may be difficult to obtain or maintain, potentially leading to narrower approved indications than desired[136]. - The company faces significant compliance costs and potential liabilities related to evolving data privacy and security regulations[154]. - Changes in government regulations could impact the demand for the company's products and services, as well as its ability to comply with new regulations[146]. - The company must navigate complex data transfer regulations following the UK's withdrawal from the EEA, increasing its compliance burden[150]. Research and Development - Research and development expenses increased to $6,016 million in 2024, up 21.4% from $4,958 million in 2023, indicating a focus on innovation[268]. - The company has invested substantial resources in developing new products, but commercialization may require additional investment and regulatory approval[133]. Financial Position and Capital Needs - The company may require additional financing to meet long-term capital requirements, with potential funding sources including equity or debt financings, but there are no commitments for such financing[86]. - The company may seek additional capital within the next twelve months to fund projected operating plans and longer-term strategic objectives[314]. - The company has never paid cash dividends and does not anticipate doing so in the foreseeable future, limiting returns on investment to stock price appreciation[164]. Customer and Vendor Concentration - Major customers accounted for 12.5% and 11.7% of revenues in 2024 from A.S. Watson Group and Life Extension, respectively[323]. - As of December 31, 2024, approximately 72% of the total outstanding trade receivables were concentrated among three customers, posing a potential risk to financial performance[329]. - The Company has a major vendor, Vendor A, accounting for 47.2% of total accounts payable as of December 31, 2024, down from 64.3% in 2023[331]. Stock and Equity - The company has approximately 10.4 million outstanding options at a weighted average exercise price of $3.27 per share, which could affect the market price of its common stock[165]. - The company may experience significant dilution of stockholder equity if future operations or acquisitions are financed through additional equity offerings[179]. - The company’s stock may be thinly traded, leading to challenges in selling shares at desired prices[178]. Environmental, Social, and Governance (ESG) Considerations - The company faces increased scrutiny regarding its environmental, social, and governance (ESG) practices, which may lead to additional costs and risks[172]. - New California laws, effective in 2026, will impose broad climate-related disclosure obligations on certain companies, potentially affecting operations and increasing expenses[172]. - Investor advocacy groups are increasingly focused on ESG practices, which may influence investment decisions away from the company if perceived inadequacies exist[174].

Company Performance - ChromaDex shares have increased by 122.5% over the past month, reaching a 52-week high of $7.85 [1] - The stock has gained 433.6% since the beginning of the year, contrasting with a -0.2% change in the Zacks Medical sector and a -8.2% return in the Zacks Medical - Biomedical and Genetics industry [1] Earnings and Revenue - ChromaDex has consistently exceeded earnings expectations, reporting EPS of $0.02 against a consensus estimate of $0.01 in its last earnings report on October 31, 2024, and beating revenue estimates by 7.93% [2] - For the current fiscal year, ChromaDex is projected to achieve earnings of $0.04 per share on revenues of $97.55 million, reflecting a 157.14% increase in EPS and a 16.73% increase in revenues [3] - The next fiscal year forecasts earnings of $0.12 per share on $120.8 million in revenues, indicating a year-over-year change of 200% in EPS and 23.83% in revenues [3] Valuation Metrics - ChromaDex has a Value Score of D, with Growth and Momentum Scores of A and C, respectively, resulting in a VGM Score of B [6] - The stock trades at 190.8X current fiscal year EPS estimates, significantly higher than the peer industry average of 22.8X, while on a trailing cash flow basis, it trades at 5X compared to the peer group's average of 14.6X [6] Zacks Rank - ChromaDex holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [7] - The stock meets the criteria for selection, as it has a Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, suggesting potential for further gains [7] Industry Comparison - In comparison to industry peers, Jazz Pharmaceuticals PLC (JAZZ) also shows strong performance with a Zacks Rank of 2 (Buy) and favorable Value, Growth, and Momentum Scores [8] - JAZZ has reported earnings exceeding consensus estimates by 20.84% and is expected to post earnings of $22.16 per share on revenues of $4.04 billion for the current fiscal year [9] - The Medical - Biomedical and Genetics industry is performing well, ranking in the top 25% of all industries, providing a positive backdrop for both ChromaDex and JAZZ [10]

Core Viewpoint - The article emphasizes the importance of identifying and sustaining trends in short-term investing, highlighting that sound fundamentals and positive earnings estimates are crucial for maintaining momentum in stock prices [1]. Group 1: Stock Performance - ChromaDex (CDXC) has shown a significant price increase of 122.6% over the past 12 weeks, indicating strong investor interest and potential upside [3]. - The stock has also experienced a price increase of 116.8% over the last four weeks, suggesting that the upward trend is still intact [4]. - CDXC is currently trading at 97.3% of its 52-week high-low range, indicating a potential breakout opportunity [4]. Group 2: Fundamental Strength - CDXC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are key indicators of near-term price movements [5]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [6]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like CDXC that are on an upward trend supported by strong fundamentals [2]. - There are over 45 Zacks Premium Screens available for investors to choose from, tailored to different investing styles and aimed at outperforming the market [7].

Core Insights - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] - ChromaDex (CDXC) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The Zacks Rank for ChromaDex is 2 (Buy), suggesting a favorable outlook for the stock based on historical performance metrics [3] Performance Metrics - ChromaDex shares have increased by 68.88% over the past week, while the Zacks Medical - Biomedical and Genetics industry has declined by 0.75% during the same period [5] - Over the last quarter, CDXC shares have risen by 105.46%, and over the past year, they have gained 376.76%, significantly outperforming the S&P 500, which increased by 15.2% and 38.09% respectively [6] - The average 20-day trading volume for CDXC is 2,538,904 shares, indicating strong trading activity [7] Earnings Outlook - In the past two months, three earnings estimates for ChromaDex have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from $0.01 to $0.04 [9] - For the next fiscal year, two estimates have moved up, while one has been revised down [9] - Overall, ChromaDex is positioned as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [9]

Company Performance - ChromaDex (CDXC) shares have increased by 72.9% over the past month, reaching a new 52-week high of $6.18 [1] - Since the beginning of the year, ChromaDex has gained 301.4%, significantly outperforming the Zacks Medical sector's 3.1% increase and the -2.3% return of the Zacks Medical - Biomedical and Genetics industry [1] Earnings and Valuation - ChromaDex has consistently exceeded earnings expectations, reporting an EPS of $0.02 against a consensus estimate of $0.01 in its latest earnings report on October 31, 2024, and beating revenue estimates by 7.93% [2] - The stock currently trades at a valuation of 246X current fiscal year EPS estimates, which is a premium compared to the peer industry average of 24.1X [5] Zacks Rank and Style Scores - ChromaDex holds a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates, indicating strong potential for further gains [6] - The company has a Value Score of D, while its Growth and Momentum Scores are both A, resulting in a combined VGM Score of B [5][6] Industry Comparison - MiMedx Group, Inc (MDXG) is a notable competitor, holding a Zacks Rank of 2 (Buy) with strong earnings performance, having beaten consensus estimates by 40% last quarter [7][8] - The Medical - Biomedical and Genetics industry is positioned in the top 38% of all industries, suggesting favorable conditions for both ChromaDex and MiMedx Group [9]

Core Viewpoint - The article emphasizes the importance of identifying sustainable trends in short-term investing, highlighting that while price momentum can be profitable, it requires strong fundamentals to maintain that momentum [1][2]. Group 1: Stock Performance - ChromaDex (CDXC) has shown a significant price increase of 103.9% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also increased by 72.9% in the last four weeks, suggesting that the upward trend is still intact [5]. - CDXC is currently trading at 91% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - CDXC holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. - Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, showcasing the effectiveness of this ranking system [7]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for identifying stocks with strong fundamentals that can maintain their upward momentum [3]. - In addition to CDXC, there are other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting further investment opportunities [8]. - The Zacks Research Wizard allows investors to backtest stock-picking strategies, enhancing the likelihood of selecting profitable stocks [9].